This work evaluates the effects of combined intravitreal antivascular endothelial growth factor (anti-VEGF) and modified panretinal photocoagulation (PRP) for management of proliferative diabetic retinopathy (PDR).
Methods:
This retrospective case series included 37 eyes of 33 patients with high-risk PDR. Anti-VEGF injections (≥ 2) were followed by modified, midperipheral PRP performed in 2 or more sessions. Visual and anatomic outcomes were tracked for 1 year after treatment. Regression analysis was performed for factors predictive of final outcomes.
Results:
Mean visual acuity (VA) at initial and final visit were 20/50 and 20/40 (P = .22), respectively, over a mean follow-up duration of 341.4 days. Central foveal thickness decreased from 321.8 µm to 258.6 µm (P = .01). Resolution of PDR was achieved in 94.6% of eyes, with 5.4% of eyes requiring additional anti-VEGF for persistent neovascularization. Final VA was significantly associated with baseline VA, VA at 1 month, and any adverse anatomical events. Treatment noncompliance was present in 24.3%; compliance decreased with increasing medical comorbidities, but was not significantly associated with final VA.
Conclusions:
Combination of anti-VEGF and modified PRP preserved VA and yielded PDR regression in the majority of eyes. This combination provides rapid PDR regression with anti-VEGF while achieving durable disease suppression in this real-world cohort without traditional PRP.
Photocoagulation treatment of proliferative diabetic retinopathy: the second report of Diabetic Retinopathy Study findings. Ophthalmol. 1978;85(1):82–106. doi:10.1016/s0161-6420(78)35693-1
3.
Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology. 1981;88(7):583–600.
4.
AntonettiDAKleinRGardnerTW. Diabetic retinopathy. N Engl J Med. 2012;366(13):1227–1239. doi:10.1056/NEJMra1005073
5.
YonekawaYModiYSKimLASkondraDKimJEWykoffCC. American Society of Retina Specialists clinical practice guidelines: management of nonproliferative and proliferative diabetic retinopathy without diabetic macular edema. J Vitreoretin Dis. 2020;4(2):125–135. doi:10.1177/2474126419893829
6.
GrossJGGlassmanARJampolLM, et al.Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA. 2015;314(20):2137–2146. doi:10.1001/jama.2015.15217
7.
GrossJGGlassmanARLiuD, et al.; Diabetic Retinopathy Clinical Research Network. Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy. JAMA Ophthalmol.2018;136(10):1138–1148. doi:10.1001/jamaophthalmol.2018.3255
8.
Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR) (PANORAMA). ClinicalTrials.gov identifier: NCT02718326. https://clinicaltrials.gov/ct2/show/study/NCT02718326. Updated November 21, 2019. Accessed June 8, 2020.
9.
HuttonDWSteinJDBresslerNMJampolLMBrowningDGlassmanAR; Diabetic Retinopathy Clinical Research Network. Cost-effectiveness of intravitreous ranibizumab compared with panretinal photocoagulation for proliferative diabetic retinopathy: secondary analysis from a Diabetic Retinopathy Clinical Research Network randomized clinical trial. JAMA Ophthalmol. 2017;135(6):576–584. doi:10.1001/jamaophthalmol.2017.0837
10.
ManiadakisNKonstantakopoulouE. Cost effectiveness of treatments for diabetic retinopathy: a systematic literature review. Pharmacoeconomics. 2019;37(8):995–1010. doi:10.1007/s40273-019-00800-w
11.
ObeidASuDPatelSN, et al.Outcomes of eyes lost to follow-up with proliferative diabetic retinopathy that received panretinal photocoagulation versus intravitreal anti-vascular endothelial growth factor. Ophthalmology. 2019;126(3):407–413. doi:10.1016/j.ophtha.2018.07.027
12.
WubbenTJJohnsonMW; Anti-VEGF Treatment Interruption Study Group. Anti-vascular endothelial growth factor therapy for diabetic retinopathy: consequences of inadvertent treatment interruptions. Am J Ophthalmol. 2019;204:13–18. doi:10.1016/j.ajo.2019.03.005
13.
FerrazDAVasquezLMPretiRC, et al.A randomized controlled trial of panretinal photocoagulation with and without intravitreal ranibizumab in treatment-naive eyes with non-high-risk proliferative diabetic retinopathy. Retina. 2015;35(2):280–287. doi:10.1097/IAE.0000000000000363
14.
ShinYWLeeYJLeeBRChoHY. Effects of an intravitreal bevacizumab injection combined with panretinal photocoagulation on high-risk proliferative diabetic retinopathy. Korean J Ophthalmol. 2009;23(4):266. doi:10.3341/kjo.2009.23.4.266
15.
ZhouAYZhouCJYaoJQuanYLRenBCWangJM. Panretinal photocoagulation versus panretinal photocoagulation plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy. Int J Ophthalmol. 2016;9(12):1772–1778. doi:10.18240/ijo.2016.12.12
16.
TonelloMCostaRAAlmeidaFPPBarbosaJCScottIUJorgeR. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol. 2008;86(4):385–389. doi:10.1111/j.1600-0420.2007.01056.x
FigueiraJFletcherEMassinP, et al.; EVICR.net Study Group. Ranibizumab plus panretinal photocoagulation versus panretinal photocoagulation alone for high-risk proliferative diabetic retinopathy (PROTEUS Study). Ophthalmology.2018;125(5):691–700. doi:10.1016/j.ophtha.2017.12.008
19.
MansourAMEl JawhariKArevaloJF. Role of peripheral pan-retinal photocoagulation in diabetic macular edema treated with intravitreal ziv-aflibercept. Clin Ophthalmol. 2019;13:695–700. doi:10.2147/OPTH.S199411
20.
BeckRWMokePSTurpinAH, et al.A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol. Am J Ophthalmol. 2003;135(2):194–205. doi:10.1016/s0002-9394(02)01825-1
21.
Schulze-BonselKFeltgenNBurauHHansenLBachM. Visual acuities “hand motion” and “counting fingers” can be quantified with the Freiburg visual acuity test. Invest Opthalmol Vis Sci. 2006;47(3):1236–1240. doi:10.1167/iovs.05-0981
22.
HolladayJT. Proper method for calculating average visual acuity. J Refract Surg. 1997;13(4):388–391.
23.
LangeCFeltgenNJunkerBSchulze-BonselKBachM. Resolving the clinical acuity categories “hand motion” and “counting fingers” using the Freiburg Visual Acuity Test (FrACT). Graefes Arch Clin Exp Ophthalmol. 2009;247(1):137–142. doi:10.1007/s00417-008-0926-0
SemeraroFMorescalchiFDuseSGambicortiECancariniACostagliolaC. Pharmacokinetic and pharmacodynamic properties of anti-VEGF drugs after intravitreal injection. Curr Drug Metab. 2015;16(7):572–584.
27.
JiangYLeidermanYI. Treatment strategy in proliferative diabetic retinopathy: anti-VEGF, laser, or both?J Vitreoretin Dis. 2018;2(5):302–304. doi:10.1177/2474126418785308
28.
MoutrayTEvansJRLoisNArmstrongDJPetoTAzuara-BlancoA. Different lasers and techniques for proliferative diabetic retinopathy. Cochrane Database Syst Rev. 2018;3:CD012314. doi:10.1002/14651858.CD012314.pub2
